AI-assisted source summary. Read the scope and exceptions, then follow the original documents below.
Applies to
InMode FY2025 manufacturer results; US surgical-pricing guidance
Time context
FY2025 results released February 10, 2026
Sources checked
The 79% figure is one manufacturer's company-wide GAAP gross margin, not an industry average, treatment margin or evidence of overcharging. The surgery example is a separate business activity.
The financial disclosure
InMode reported a 79% GAAP gross margin and a 23% GAAP operating margin for full-year 2025. The difference matters: gross profit is measured before operating expenses. These manufacturer-level figures do not reveal what a clinic earns from one customer's procedure.
ASPS explains that its rhinoplasty surgeon-fee estimate excludes anesthesia, operating-room facilities and other expenses. That is an example of why an advertised component price cannot be compared directly with another clinic's all-in quote.
Our checklist: request the exact procedure, product or device, practitioner, number of sessions and included follow-up. Ask which anesthesia, facility and complication-related costs are separate. Neither a high price nor a discount proves quality; compare the same scope before judging the markup.
Original documents used for this summary. Multiple links from one publisher are not independent corroboration. Policies can change after the check date.
AI-assisted research, writing and translation by No Secrets, using the linked public documents. This is a source summary, not firsthand reporting or an independently audited investigation. No affiliate links are used in this article.
The date above records this research pass, not the date of every underlying event. The English and Chinese versions are AI-assisted summaries; the linked original controls if they differ.